PROTAC logic continues to evolve
New publications highlight bispecific antibody degraders as a way to eliminate a cell surface target
Academics and companies are developing PROTAC-adjacent methods that overcome some of the hurdles of the modality such as complex design, poor bioavailability due to large size, and limitation to intracellular targets.
The TAC field took off with modular compounds known as proteolysis targeting chimeras (PROTACs), which ubiquitinate targets and send them to the proteasome for degradation. These bivalent structures use a linker to connect separate ligands for a target of interest and an E3 ligase...
BCIQ Company Profiles
BCIQ Target Profiles
Asialoglycoprotein receptor 1 (ASGR1) (ASGPR) (CLEC4H1)
CXC chemokine receptor 7 (CXCR7)
Chemokine CXC motif ligand 12 (CXCL12) (SDF-1)
Epidermal growth factor receptor (EGFR) (ErbB1) (HER1)
Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Insulin-like growth factor-1 (IGF-1) receptor (IGF1R) (CD221)